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Abstract. Triclabendazole (TCBZ) is a veterinary drug used 
against Fasciola hepatica in cattle. The Cajamarca Valley in Peru 
is an endemic area of fascioliasis with a high infection rate in 
animals producing milk for human consumption. The 
administration of TCBZ during the lactating period can lead to 
TCBZ derivative residues in milk and cheese entering the human 
food chain. Milk-derivatives from treated animals have been found 
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positive for TCBZ metabolites. One of these metabolites, triclabendazole sulfoxide 
(TCBZSO), is embryolethal during early developmental stages in vitro in mouse 
and zebrafish. In this study, we have calculated the estimated daily intake (EDI) of 
TCBZSO due to milk and cheese consumption among a rural population in 
Cajamarca in order to evaluate the associated risk for human embryonic 
development. Although the expected maximum plasma concentration of TCBZSO 
after a worst-case scenario simulation would be below the reported lowest 
observed adverse effect concentration (LOAEC) for embryolethality in vitro                 
(10 µM), several limitations on the available information for exposure, 
bioavailability and interspecies differences still impede the accomplishment of an 
accurate risk assessment. 
 
Introduction 
 
  Triclabendazole (TCBZ) is a benzimidazolic compound used in 
veterinary medicine to treat fascioliasis. This parasitic disease, induced by 
the liver trematode Fasciola hepatica (see life cycle in Fig.1 [1]) is endemic 
in the Cajamarca Valley in Peru, where more than 78% of livestock are 
infected [2]. Treating the infected animals is a necessity in order to reduce 
the number of hosts and thus to reduce the disease impact in humans, but 
also to avoid production losses in cattle industry by means of reductions in 
animal weight gain, fertility and milk yield [3-5]. TCBZ is the drug of choice 
to treat fascioliasis in animals because it has high activity against adult and 
juvenile flukes [6-8] and because it can be administered as a single treatment 
at the start of the dry-off period, when no milk is being produced for human 
consumption, and thus avoid TCBZ residues in milk [9]. 
 However, in fascioliasis endemic areas like Cajamarca, TCBZ treatment 
is administered three to four times a year, even during the period when cows 
produce milk for human consumption [10]. This use during the lactating 
period can lead to TCBZ derivative residues entering the human food chain 
as several studies have shown the presence of TCBZ residues in milk and its 
transference to dairy products [9].  
 Taking that into consideration, a maximum residue limit (MRL) of          
10 µg/kg of TCBZ in milk has been fixed by the European Union [11], and 
also an acceptable daily intake (ADI) of TCBZ of 0 to 3 µg/kg body weight 
(b.w). [12]. However, neither MRL has been established for TCBZ 
derivatives in milk, nor for TCBZ or TCBZ derivatives in cheese and other 
dairy products. The presence of these residues in the human food chain 
acquires special relevance when considering that triclabendazole sulfoxide 
(TCBZSO), the first metabolite of TCBZ, presents embryotoxic potential            
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in vitro in mouse and zebrafish (lowest observed adverse effect 
concentration for lethality; LOAEClethality = 10 µM; [13]). Therefore, our aim 
was to evaluate the possible risk for human embryonic development derived 
from maternal consumption of milk and cheese containing TCBZ derivative 
residues during gestation. 
  
 
 
Figure 1. Life cycle of Fasciola hepatica and Fasciola gigantica [1].  
Immature eggs are discharged in the biliary ducts and in the stool. (1) Eggs become 
embryonated in water (2), eggs release miracidia (3), which invade a suitable snail 
intermediate host (4), including the genera Galba, Fossaria and Pseudosuccinea. In 
the snail the parasites undergo several developmental stages [sporocysts (4a), rediae 
(4b), and cercariae (4c)]. The cercariae are released from the snail (5) and encyst as 
metacercariae on aquatic vegetation or other surfaces. Mammals acquire the infection 
by eating vegetation containing metacercariae. Humans can become infected by 
ingesting metacercariae-containing freshwater plants, especially watercress (6). After 
ingestion, the metacercariae excyst in the duodenum (7) and migrate through the 
intestinal wall, the peritoneal cavity, and the liver parenchyma into the biliary ducts, 
where they develop into adults (8). In humans, maturation from metacercariae into 
adult flukes takes approximately 3 to 4 months. The adult flukes (F. hepatica: up to 
30 mm by 13 mm; F. gigantica: up to 75 mm) reside in the large biliary ducts of the 
mammalian host. F. hepatica parasites can infect various animal species, mostly 
herbivores (source [1]). 
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1. Presence of triclabendazole-derivative residues in milk and 
cheese samples 
 
 TCBZ-derivative concentrations in milk and cheese samples were 
obtained from a study carried out on a dairy farm situated in Cajamarca, 
Peru [10]. In this study by Imperiale et al., seven female Holstein dairy 
cows between 490 and 630 kg weight were orally treated with a single 
dose of 12 mg TCBZ/ kg b.w. (Fasinex®, TCBZ 10%, Novartis). Milk 
samples were collected prior to treatment and at 6, 12, 24, 36, 48, 60, 72, 
84, 96, 120 and 144 h post-treatment. Approximately 50 mL of milk were 
collected after homogenization of the whole milk yield of each cow. The 
remaining milk production of all experimental animals collected at 12, 24, 
36, 48, 60 and 120 h post-treatment was pooled and processed to produce 
creamy cheese. The extraction procedures to quantify TCBZ and its 
metabolites in milk (0.5 mL) and cheese (0.5 g) samples were carried out 
following modifications of previously described methods [10, 14, 15]. 
Drug concentrations in experimental samples were determined by HPLC 
with a UV detector using oxibendazole as internal standard (99.2% purity). 
Both TCBZSO and triclabendazole sulfone (TCBZSO2) metabolites but 
not TCBZ were detected in milk (up to 36 and 144 h post-treatment, 
respectively). The sum of total residues (TCBZSO and TCBZSO2) was 
between 0.6 and 2 µg/mL in pooled milk, and between 1.1 and 20.0 µg/g in 
cheese. 
 
2. Milk and cheese consumption data 
 
 Milk and cheese consumption data concerning the rural population of 
Cajamarca valley were obtained from two different studies, one from our 
own group [16] and one from an official Peruvian dietary survey (INEI) 
[17]. Briefly, in our own study, 36 people from 11 populations located in 
the rural area of Cajamarca were interviewed for a 24 h dietary recall. To 
contrast and compare the obtained information, a qualitative food 
frequency questionnaire was performed by the same interviewer to the 
same individuals. The official dietary survey of Peru [17] collected 
information from seven days questionnaires of 1536 households in rural 
areas and 34698 households in urban areas of Peru. The areas covered in 
the study included coast, mountains and rainforest.  
 Milk consumption results reported by these two studies were very 
different. These differences can be explained by the fact that the INEI 
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study covered the whole Peruvian population, while the study from 
Barenys et al. [16] was performed exclusively in the Cajamarca valley, 
which is one of the main milk and dairy producer regions in Peru [18]. 
Besides, the population interviewed, consisted mainly in teenagers (63% of 
participants were people between 14 and 17 years old), which are 
described to consume more milk than the adult population [19]. 
 Ideally, the consumption data should be obtained from women at 
childbearing age, but this consumption values are not available for the 
whole Peruvian population [17], and the sample size of this group was too 
small to drive conclusions in the study by Barenys et al. [16]. We have 
used the values reported in both studies [16, 17] for milk and cheese 
consumption to further calculate the Estimated Daily Intake (EDI) of 
TCBZ derivatives.  
 
3. Triclabendazole derivatives estimated daily intake calculation 
 
 The results obtained by Imperiale et al. [10] for TCBZSO and TCBZSO2 
concentrations in milk and cheese and the contribution of milk and cheese to 
the diet according to our 24 h dietary recall results, and the INEI survey [17] 
are detailed in Table 1 and were used to calculate the EDI of TCBZ 
derivatives per individual, expressed in µg of TCBZ derivatives/kg b.w. per 
day, as follows: 
 
 
 
 
The median weight value for women population was obtained from 
Ministerio de Salud del Perú [20]. As detailed in Table 1, the EDI of 
TCBZSO + TCBZSO2 in a worst-case scenario approach was estimated to 
be 12.0 µg/kg b.w. 
  
     
 
  
 It is important to remark that there is no study available from the region of 
Cajamarca indicating which is the real presence of TCBZ derivatives in 
representative samples in the market and thus, which would be the mean real 
exposure in the general population. Therefore, the TCBZ derivative values 
described in Imperiale et al., [10], obtained in only one farm directly after the 
administration of TCBZ to the animals, were taken to simulate a worst-case 
scenario and to study its associated risk for human embryonic development. 
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Table 1. Triclabendazole derivatives estimated daily intake calculation. 
 
Median 
woman 
body 
weight 
[kg] 
Milk 
consumption 
[mL] 
Cheese 
consumption 
[g] 
TCBZSO+TCBZSO2 
concentration in 
milk [µg/mL] 
TCBZSO+TCBZSO2 
concentration in 
cheese [µg/g] 
TCBZSO+TCBZSO2 
Estimated Daily 
Intake [µg/kg b.w.] 
 Perú Caj Perú Caj   Worst-case scenario 
50a 107b 180.2c 12.0b 8.98d 2e 20e 12.0 
Perú: data from the 5th quintile of the INEI survey [17], milk consumption includes milk and yoghurt; Caj: data from 24-h  
dietary recall to Cajamarca population [16]; a: [20]; b: [17] (milk consumption corresponding to milk and yoghurt values);  
c: calculated from g to mL from [16] using milk density=1.03; d: [16]; e: [10].  
 
4. Plasma concentration-ranges after the estimated daily intake vs 
LOAEC for embryo lethality in vitro 
 
 In humans, after ingestion of a therapeutic dose of 10 mg/kg b.w. of 
TCBZ, the obtained maximum plasma concentration (Cmax) of TCBZSO is 
38.6 μM [21]. At present, there is no characterization of TCBZSO Cmax 
reached after direct administration of TCBZSO in humans or in animals, but 
pharmacokinetic studies with other benzimidazoles have compared the 
reached concentrations of the sulfoxide metabolite after the administration of 
the parent compound or after the administration of the sulfoxide metabolite 
itself [22, 23, 24]. 
 For example, albendazole sulfoxide (ABZSO) produced significantly 
higher ABZSO Cmax but not significantly higher area under the curve (AUC) 
than albendazole (ABZ) in 1-month-old lambs, and significantly higher 
ABZSO Cmax and AUC than ABZ in 8-month-old lambs following 
administration of 5 mg/kg b.w. of each compound [22]. These differences 
were comparable to those determined previously in goats [22, 23]. Similarly, 
the plasma concentration of fenbendazole sulfoxide (FBZSO) was much 
greater when it was directly administered than when fenbendazole (FBZ) 
was administered in horses, at 10 mg/kg b.w. each. It is remarkable that 
FBZSO achieved 25.6 or 35 times greater concentrations (expressed as AUC 
or Cmax, respectively) when it was directly administered, than after 
administration of the parent compound [24]. These studies show that when 
the sulfoxide metabolite is directly administered, the plasma concentration 
seems to be similar or higher than when the parent compound is 
administered at the same doses. 
 Anyhow, a precise characterization of the Cmax of TCBZSO after 
TCBZSO administration is still missing and would be essential for a correct 
risk assessment of TCBZSO effects on human development. 
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Figure 2. Graphical summary comparing TCBZSO results across species and 
developing time.  
Representative pictures of rodent embryos exposed to increasing concentrations of 
TCBZSO from GD 0 to GD 4 in the preWEC culture (LOAEClethality= 10 µM) and 
from GD 9.5 to GD 11.5 in the postWEC culture (LOAECdysmorphogenesis= 666 µM). 
Zebrafish embryos were exposed to TCBZSO from 2 hpf to 50 hpf, a developmental 
period comprising the stages covered by both rodent cultures. No dysmorphogenesis 
were observed (maximum concentration tested= 50 µM), but TCBZSO was embryo 
lethal during the first 24 h of culture (LOAEClethality= 10 µM). Pictures correspond to 
the developmental time points marked in bold in the x-axis. Pictures of pre WEC 
embryos are 10 times magnified respect to pictures of post WEC and zebrafish 
embryos.  
Scale bar: 4 mm for post WEC and zebrafish embryos; and 400 µm for pre WEC 
embryos.  
ZFET: zebrafish embryo test (concentrations= 0, 5, 10 and 50 µM); pre WEC: 
preimplantation whole embryo culture (concentrations= 0, 3, 10, 30 and 100 µM); 
postWEC: postimplantation whole embryo culture (concentrations= 0, 27, 267 and 
666 µM); GD: gestational day; hpf: hours post-fertilization (ref. [13]). 
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 Taking into account this important limitation, after the administration of 
the TCBZSO EDI of 12.0 µg/kg b.w., the plasma Cmax could be calculated 
following a simplified approach which considers total and instant absorption 
and no tissue distribution: 
 
 
 
  
 Total plasma volume was obtained following the standard weight-
based calculation for normal females (0.04L x kg b.w.) [25]. 
 This concentration is still lower than the experimental LOAEC for 
embryotoxicity observed in in vitro developmental toxicity tests in mouse 
and zebrafish (LOAEClethality= 10 µM; [13]; see Fig 2), but the lack                                   
of specific pharmacokinetic data after TCBZSO administration                       
and the possible species differences in pharmacokinetics and embryo 
toxicity sensitivity, pose a serious obstacle to an accurate risk assessment 
process. 
 
5. Discussion 
 
 At present, no MRL has been established for TCBZSO in milk, in 
cheese or in other dairy products. Likewise, no ADI has been established 
for TCBZSO. However, there is extensive scientific evidence that flukicide 
administration to milk producing animals leads to migration of residues to 
milk and its derived products as cheese, butter and skim milk powder. It is 
remarkable that pasteurization or heat treatment during spray drying have 
no impact in reducing these residues [9]. 
 The present study approaches the subject of risk assessment of TCBZ 
residues in milk and cheese in the diet of a rural population in Cajamarca 
(Peru). However, several limitations on the current knowledge about 
exposure characterization, bioavailability of the compound and 
interspecies differences in sensitivity impede an accurate accomplishment 
of the risk assessment process. 
 
 Limitations on exposure characterization: in section 3 we have 
calculated the EDI of total TCBZ derivatives considering a worst-case 
scenario, as the concentrations used for the calculations are from milk and 
cheese samples obtained from cows after controlled administration of 
TCBZ [10]. But in a real situation, not all milk and cheese products 
consumed by the population would contain TCBZ derivative residues. 
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Currently, there are no studies detailing the prevalence of milk and cheese 
samples containing TCBZ derivatives in the Cajamarca market. A study 
comparable to the one performed by [26] where 27.6% of raw milk 
samples collected from all farms throughout Southern Greece were found 
to be positive for the investigated benzimidazoles, would be very valuable 
to better characterize the real exposure scenario.  
 Besides, in the EDI calculation, the sum of both metabolites (TCBZSO 
and TCBZSO2) has been considered, as no concentration values for 
TCBZSO alone have been detailed. However, the embryotoxic potential of 
TCBZSO2 has not been investigated yet and it is a shortcoming of the 
current approach to consider it as if it would be as potent as TCBZSO and 
work further on with the EDI value obtained from the sum of both 
metabolites. 
 
 Limitations on bioavailability information: as detailed in section 4, 
there is no specific pharmacokinetic data about TCBZSO bioavailability 
after TCBZSO administration in humans, neither in animals. A simplified 
calculation of Cmax has been used for approximation, but real 
pharmacokinetic data would help to carry a more accurate risk assessment. 
 
 Limitations on information about interspecies differences: 
Embryolethality (LOAEClethality) from in vitro developmental toxicity tests has 
been established at 10 µM using the mouse preimplantation embryo culture 
and the zebrafish embryo models [13]. However, there is growing recognition 
that to predict human safety, it would be advisable to know if there are species 
differences in sensitivity towards TCBZSO embryo lethal effects [27], by 
conducting other studies like parallel human and mouse embryonic stem cell 
tests. 
  
6. Conclusions 
 
 In this study we have calculated the EDI of TCBZ derivatives simulating 
a worst-case scenario. After a TCBZSO EDI, the expected Cmax would be 
lower than the experimental LOAEC for embryotoxicity observed in in vitro 
developmental toxicity tests in mouse and in zebrafish. However, our study 
highlights the current needs of information to carry out an accurate risk 
assessment for TCBZSO exposure during human development. Specifically, 
there is a need of:  
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 A better characterization of TCBZSO presence in commercialized 
milk and milk-derivatives samples with concrete TCBZSO 
concentrations. 
 A detailed pharmacokinetic profile of TCBZSO concentrations 
reached after TCBZSO intake.  
 More information on human sensitivity towards TCBZSO embryo 
lethality from human 3D in vitro models. 
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